Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...

Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping ...

The firm will seek accelerated approval for WVE-N531 in DMD amenable to exon 53 skipping based on FDA feedback and Phase II data.

The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.

The beginning to the year has been eventful in the Duchenne muscular dystrophy (DMD) space, with several trial readouts announced at the Muscular Dystrophy Association (MDA) 2025 meeting ...

Shares of Wave Life Sciences Ltd . (NASDAQ: WVE) rose 14% today, following the company’s announcement of positive results from its FORWARD-53 clinical trial in Duchenne muscular dystrophy (DMD), which ...

The company also anticipates submitting clinical trial applications for multiple DMD candidates targeting other exons in 2026. The FORWARD-53 trial enrolled eleven boys, with biopsy data from eight ...

Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...

Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy (DMD). Results from the company’s ...